-
Galecto is developing galectin-3 inhibitors targeting both macrophages and fibroblasts, which it expects to provide potent inhibition of fibrosis in IPF by itself and in combination with other compounds.
Published on 5/14/2012
-
Galecto: Two-pronged attack Galecto Biotech AB Lund, Sweden Technology: Galectin modulators Disease focus: Pulmonary, inflammation, cancer Clinical status: Preclinical Founded: 2011 by Hakon Leffler, Ulf Nilsson…
Published on 5/14/2012
-
Visionary: Sights on drug design Visionary Pharmaceuticals Inc. San Diego, Calif. Technology: Structure-based drug design Disease focus: Autoimmune, inflammation Clinical status: Preclinical Founded: 2010 by …
Published on 5/14/2012
-
Visionary believes a large library and computational technology that accounts for conformational changes will allow it to design more drug-like small molecules than those discovered by conventional HTS.
Published on 5/14/2012
-
Essa: A baby Cougar Essa Pharma Inc. Vancouver, B.C. Technology: Small molecule inhibitor of the N-terminus of the androgen receptor Disease focus: Cancer Clinical status: Preclinical Founded: 2009 by Marianne …
Published on 5/7/2012
-
Essa is developing a next-generation androgen receptor antagonist that blocks a previously intractable domain, a strategy the company expects to work even after other drugs have failed.
Published on 5/7/2012
-
Principia is developing small molecule reversible covalent inhibitors it believes will have fewer off-target effects and lower immunogenicity than irreversible inhibitors.
Published on 5/7/2012
-
Principia: Reversing covalency Principia Biopharma Inc. South San Francisco, Calif. Technology: Covalent reversible inhibitors using a reactive cyanoacrylamide group Disease focus: Cancer, Autoimmune Clinical …
Published on 5/7/2012
-
Ariel: Antagonizing pain Ariel Pharmaceuticals Inc. Broomfield, Colo. Technology: Prostaglandin E2 (PGE2) receptor EP4 subtype (prostanoid EP4 receptor; PTGER4) antagonists Disease focus: Neurology Clinical …
Published on 4/30/2012
-
Ariel is developing a PTGER4 antagonist that it believes could be safer than standards of care for migraine and osteoarthritis, while also being effective in nonresponders to SOC.
Published on 4/30/2012
-
Vascular Magnetics: A long-term force Vascular Magnetics Inc. Philadelphia, Pa. Technology: Drug-loaded magnetic particles delivered via a superparamagnetic catheter and external magnetic field Disease focus: Drug…
Published on 4/30/2012
-
Vascular Magnetics is developing its Vascular Magnetics Intervention system for targeted delivery of sustained doses of anti-restenotic drugs in patients with peripheral artery disease.
Published on 4/30/2012
-
APIM: Besting the stress defense APIM Therapeutics A/S Trondheim, Norway Technology: Peptide-based inhibitors of proliferating cell nuclear antigen (PCNA) Disease focus: Cancer Clinical status: Preclinical …
Published on 4/23/2012
-
APIM is targeting a master switch that regulates cellular stress responses to increase the efficacy of multiple myeloma therapies.
Published on 4/23/2012
-
Hitting the links ProLynx LLC Hayward, Calif. Technology: Linkers for carrier-drug conjugates Disease focus: Drug delivery, endocrine/metabolic, cancer Clinical status: Preclinical Founded: 2009 by Gary Ashley …
Published on 4/23/2012
-
ProLynx's conjugate linkers increase a drug's duration of action by releasing therapeutics at consistent, preprogrammed rates, which the company thinks can overcome drawbacks of other conjugate technologies.
Published on 4/23/2012
-
Aerpio: Stanching the leak Aerpio Therapeutics Inc. Cincinnati, Ohio Technology: Tyrosine kinase receptor 2 (Tie2) activator Disease focus: Ophthalmology, autoimmune Clinical status: Phase I Founded: 2011 by …
Published on 4/16/2012
-
Aerpio's Tie2 activator not only could be more effective than VEGF inhibitors for diabetic macular edema, but also could treat co-morbidities such as diabetic nephropathy.
Published on 4/16/2012
-
Ceronco: Gateway into the cell Ceronco BioSciences B.V. Den Haag, the Netherlands Technology: Short chain sphingolipid delivery technology Disease focus: Cancer Clinical status: Preclinical Founded: 2011 by …
Published on 4/16/2012
-
Ceronco's short chain sphingolipid delivery technology preferentially increases uptake of chemotherapeutics into cancer cells, which could improve efficacy without increasing toxicity.
Published on 4/16/2012
-
Arteaus: Meeting of minds Arteaus Therapeutics LLC Cambridge, Mass. Technology: Antibody targeting calcitonin gene-related peptide (CGRP) for migraine prevention Disease focus: Neurology Clinical status: Phase I…
Published on 4/9/2012
-
Arteaus, the first company formed by Atlas Venture's AVDC initiative, has taken on Lilly's antibody against CGRP, potentially the first new target to prevent migraine in decades.
Published on 4/9/2012
-
Rubigo's polymeric film technology provides site- and dose-specific delivery of the generic imiquimod for actinic keratosis, which it expects to avoid the adverse events reported with topical cream formulations.
Published on 4/9/2012
-
Rubigo: Safety in film Rubigo Therapeutics Inc. St. Paul, Minn. Technology: Polymeric film delivery platform Disease focus: Drug delivery, dermatology Clinical status: Preclinical Founded: 2011 by Stan Harpstead…
Published on 4/9/2012
-
Arsanis: Antibodies for infection Arsanis Inc. Vienna, Austria Technology: Antibodies to treat infectious diseases Disease focus: Infectious Status: Preclinical Founded: 2010 by Errik Anderson, Tillman Gerngross…
Published on 4/2/2012